Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • FAK
    (1)
  • Integrin
    (1)
  • Liposome
    (1)
  • Serine/threonin kinase
    (1)
  • Src
    (1)
  • VEGFR
    (1)
  • Others
    (2)
Filter
Search Result
Results for "

neovascular

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    1
    TargetMol | Inhibitory_Antibodies
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Cell Research
    1
    TargetMol | Inhibitors_Agonists
Brolucizumab
RTH258, ESBA 1008, DLX1008
T805931531589-13-5
Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).
  • $813
In Stock
Size
QTY